Novo Nordisk Healthcare Ag

Novo Nordisk A/s

Daniel E Rasmussen

Arne Staby

Janus Krarup

Haleh Ahmadian

Susanne Bang

Thomas Budde Hansen

Are Bogsnes

Anne Charlotte Arentsen

Niels Kristian Klausen

Ole Schou

John Strikart Nielsen

The present invention relates to compositions comprising glycoproteins having altered patterns of O-linked glycosylation, in particular Factor VII, Factor IX, and methods for making these.

O-linked glycoforms of polypeptides and method to manufacture them

The present invention relates to Vitamin K-dependent protein compositions having a very low, or negligible, content of protein contaminants. The present invention also relates to method applicable in the preparation of such Vitamin K-dependent protein compositions. Such methods may either be used alone or in sequential combination with the purpose of reducing the relative content of protein contaminants. The present invention is particularly relevant in the preparation of compositions of coagulation factors selected from Factor X polypeptides (FX/FXa), Factor IX polypeptides (FIX/FIXa), Factor VII polypeptides (FVII/FVIIa), and the anticoagulant Protein C, in particular Factor VII polypeptides.

Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest

The invention described herein provides new methods of preparing purified Factor VII polypeptide drug substances in large quantities (industrial scale levels) that are associated with reduced content of product-related impurities (e.g., late eluting peaks) and/or that exhibit a relatively uniform glycosylation pattern.

Hydrophobic interaction chromatography purification of factor VII polypeptides

The present invention provides a method for industrial-scale protein separation by reverse phase chromatography by use of a buffer system and an additional salt.

Purification of proteins using preparative reverse phase chromatography (RPC)

Growing community of inventors

Copenhagen, Denmark

Daniel E Rasmussen